February 8, 2007 -- GlaxoSmithKline announced results today. As expected, there was plenty of good news. Sales are brisk. Profit was up 5%. And among those numbers was a once little known drug, called Requip, that is now performing spectacularly well. Total sales for Requip in 2006 topped out at $496 million. And to think that Requip is aimed at a disease few people knew about only five years ago. This did not happen without some help from the marketing groups at Glaxo. More...
